10 янв. 2024 г. · Learn more about the new FDA-approved drug repotrectinib (AugtyroTM), which targets ROS1 fusions in lung cancer and other cancer types.

31 мая 2024 г. · “Lorlatinib is the only ALK TKI that has reported five-year progression-free survival, and even after this time, the majority of patients ...

21 авг. 2024 г. · The new combined Lazcluze-Rybrevant therapy is now FDA-approved for adults with certain types of non-small-cell lung cancer that has progressed ...

The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation.

5 июл. 2023 г. · Osimertinib, which is taken daily as a pill, specifically targets and kills lung cancer cells with these genetic mutations. ... The findings “ ...

17 мая 2024 г. · Importantly, tarlatamab (Imdelltra) is only for patients who have exhausted all other options to treat extensive-stage small cell lung cancer.

3 июн. 2024 г. · Lorlatinib is a third-generation ALK inhibitor, the newest in a class of drugs that are the standard first-line treatment for patients with ALK- ...

5 дней назад · Drugs Approved for Small Cell Lung Cancer · Afinitor (Everolimus) · Atezolizumab · Atezolizumab and Hyaluronidase-tqjs · Doxorubicin Hydrochloride ...

8 июн. 2024 г. · Indication: TAGRISSO® is used for the treatment of early-stage epidermal growth factor receptor mutation (EGFRm) positive non-small cell lung ...

31 мая 2024 г. · Lorbrena is specifically approved as a first-line treatment for that form of lung cancer, meaning patients who take it have not received any ...